Welcome to our dedicated page for Rockwell Med news (Ticker: RMTI), a resource for investors and traders seeking the latest updates and insights on Rockwell Med stock.
Rockwell Medical, Inc. (Nasdaq: RMTI) is a healthcare company that develops, manufactures, commercializes, and distributes hemodialysis products for dialysis providers worldwide. The Rockwell Medical (RMTI) news feed on Stock Titan focuses on company announcements that relate to its hemodialysis concentrates portfolio, supply agreements with dialysis providers, operational updates, and financial results.
Investors and healthcare observers following RMTI news can expect coverage of product purchase agreements with large dialysis providers, health systems, and specialized care organizations. Recent company communications describe multi-year contracts that include utilization or purchase minimums, options to renew, and supply of liquid and dry acid and bicarbonate concentrates, as well as Rockwell Medical’s dry acid concentrate mix system and bicarbonate cartridge. News items also highlight the company’s efforts to expand its customer base, including adding new dialysis customers in different regions of the United States.
The RMTI news stream also includes quarterly financial and operational results, typically released through earnings press releases and accompanied by conference call details. These updates discuss net sales, gross margin, adjusted EBITDA, and cash position, along with commentary on customer transitions, contract renewals, and manufacturing efficiency. In addition, Rockwell Medical issues news on leadership changes, such as board appointments and executive promotions, and on operational roles related to manufacturing and supply chain management.
Further topics in Rockwell Medical news include participation in industry events, such as exhibiting its hemodialysis concentrates portfolio at professional nephrology conferences, and recognition as a Great Place to Work® and a Fortune Best Workplaces in Manufacturing & Production™ honoree. For users tracking RMTI, this news page provides a centralized view of the company’s corporate developments, financial disclosures, and updates on its hemodialysis products and customer relationships.
Rockwell Medical, Inc. (Nasdaq: RMTI) announced pivotal findings published in the Journal of Bioequivalence & Bioavailability regarding the co-administration of Ferric Pyrophosphate Citrate (FPC, Triferic®) with unfractionated heparin (UFH) during hemodialysis. The study confirmed no significant drug-drug interactions affecting anticoagulation efficacy. Notably, over 1.6 million doses of FPC have been safely administered, supporting its FDA-approved use to maintain hemoglobin in hemodialysis patients. Triferic represents a significant advancement in managing iron deficiency in this population.
Rockwell Medical (RMTI) reported third-quarter net sales of $16.0 million, reflecting a 6% sequential and 5% year-over-year increase. The growth was mainly driven by dialysis concentrates, which generated approximately $15.7 million. The company submitted an Investigational New Drug application for Ferric Pyrophosphate Citrate (FPC), targeting iron deficiency anemia treatment in patients receiving home infusion. It also presented real-world evidence data at ASN Kidney Week 2021, showing the effectiveness of Triferic in maintaining hemoglobin levels in chronic hemodialysis patients.
Rockwell Medical (RMTI) announced the approval of option grants for two new employees, allowing them to purchase a total of 75,000 shares of common stock. This was done as an inducement for their employment, in line with Nasdaq rules, and the exercise price is set at $0.53, matching the closing stock price on the grant date, November 10, 2021. The options will vest over three years, contingent on continued employment. Rockwell Medical specializes in biopharmaceuticals, focusing on iron deficiency treatments and offers two FDA-approved therapies for hemodialysis patients.
Rockwell Medical (RMTI) announced the submission of an Investigational New Drug (IND) application to the FDA for its Phase 2 clinical trial of Ferric Pyrophosphate Citrate (FPC). This treatment targets iron deficiency anemia in patients undergoing home infusion therapy. The CMO emphasized the inadequacies of current treatment methods for this patient population, which often leads to severe fatigue and health risks. The company aims to expand the use of FPC beyond dialysis, marking a significant milestone in its development pipeline.
Rockwell Medical (Nasdaq: RMTI) announced a conference call scheduled for November 15, 2021, at 4:00 PM ET to discuss its Q3 financial results and operational highlights. Investors can participate by dialing (877) 383-7438 or (678) 894-3975, using conference ID 7697945. A live webcast will be available on the company's website, with an archived version accessible for 30 days post-event. Rockwell specializes in biopharmaceuticals, focusing on iron deficiency treatments and is a major supplier of hemodialysis products in the U.S.
Rockwell Medical presented findings at ASN Kidney Week 2021, highlighting positive results from a pilot observational analysis on Triferic (Ferric Pyrophosphate Citrate) for hemodialysis patients. The study showed a 23% reduction in IV iron usage during the first three months, increasing to 81% reduction with a new iron management protocol. Hemoglobin levels remained stable throughout. These results align with prior pivotal trials and suggest potential cost savings in anemia management for dialysis clinics.
Rockwell Medical (Nasdaq: RMTI) announced participation in the H.C. Wainwright 23rd Annual Global Investment Conference, scheduled for September 13-15, 2021. The company's executive management team will present virtually, and the presentation will be available on-demand starting September 13 at 7:00 a.m. ET on their website. Additionally, management will engage in one-on-one meetings with registered investors. Rockwell Medical is focused on innovative treatments for iron deficiency and has two FDA-approved therapies for hemodialysis patients.
Rockwell Medical, Inc. (Nasdaq: RMTI) announced the approval of an option to purchase 350,000 shares of its common stock to Megan C. Timmins, Senior VP and General Counsel. This Inducement Grant, effective August 16, 2021, has an exercise price of $0.61 and will vest over four years in two equal installments. The grant aligns with Nasdaq Listing Rule 5635(c)(4) and is outside the 2018 Long Term Incentive Plan. Rockwell Medical focuses on iron deficiency treatments and is a supplier of hemodialysis concentrate products in the U.S.
Rockwell Medical has announced a licensing agreement with Drogsan Pharmaceuticals to commercialize Triferic in Turkey and extended its distribution contract with Nipro Medical for dialysis concentrates in LATAM and the Caribbean. In Q2 2021, Rockwell reported net sales of $15.1 million, down from $15.9 million in Q2 2020, largely due to pandemic-related impacts. The company identified a gross loss of $0.3 million, with increased operating expenses resulting in a net loss of $8.4 million for the quarter. Cash reserves stand at approximately $41 million, supporting strategic initiatives.
Rockwell Medical (Nasdaq: RMTI) announced a conference call on August 16, 2021, at 4:30 p.m. ET to discuss its financial results for Q2 2021 and operational updates. Investors can join the call by dialing (877) 377-7548 locally or (760) 666-3756 internationally, referencing conference ID 1254179. A live webcast will also be available on the company's investor website with an archived version accessible for 30 days. Rockwell Medical is focused on transforming iron deficiency treatment with its proprietary Ferric Pyrophosphate Citrate technology.